Kelly Lawrence W & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Kelly Lawrence W & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,100	Closed	-$221K	–	214
2016 Q4	$221K	Hold	6,100	–	–	0.05%	88
2016 Q3	$281K	Hold	6,100	–	–	0.06%	83
2016 Q2	$306K	Hold	6,100	–	–	0.07%	82
2016 Q1	$326K	Hold	6,100	–	–	0.08%	69
2015 Q4	$400K	Hold	6,100	–	–	0.09%	63
2015 Q3	$344K	Hold	6,100	–	–	0.08%	69
2015 Q2	$361K	Hold	6,100	–	–	0.07%	73
2015 Q1	$380K	Hold	6,100	–	–	0.08%	65
2014 Q4	$351K	Sell	6,100 -6,717	-52%	-$374K	0.07%	68
2014 Q3	$689K	Hold	12,817	–	–	0.15%	53
2014 Q2	$672K	Sell	12,817 -50	-0.4%	-$2.56K	0.14%	54
2014 Q1	$680K	Buy	12,867 +50	+0.4%	+$2.31K	0.16%	54
2013 Q4	$514K	Sell	12,817 -17,965	-58%	-$707K	0.11%	60
2013 Q3	$1.16M	Hold	30,782	–	–	0.28%	45
2013 Q2	$1.21M	Buy	+30,782	New	+$1.2M	0.31%	43

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kelly Lawrence W & Associates's TEVA Position: Q1 2017 in Review

Kelly Lawrence W & Associates sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 6,100 shares — an estimated $221K sold.

Kelly Lawrence W & Associates first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $1.21M in Q2 2013. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Kelly Lawrence W & Associates reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Kelly Lawrence W & Associates sold 6,100 Teva Pharmaceuticals shares in Q1 2017, an estimated $221K.
Kelly Lawrence W & Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Kelly Lawrence W & Associates's Teva Pharmaceuticals position peaked at $1.21M in Q2 2013.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Kelly Lawrence W & Associates's 13F filing for Q1 2017, filed 15 May 2017.